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ARTICLE
Widespread anti-CRISPR proteins in virulent
bacteriophages inhibit a range of Cas9 proteins
Alexander P. Hynes 1,2, Geneviève M. Rousseau 1, Daniel Agudelo 3, Adeline Goulet4,5,
Beatrice Amigues4,5, Jeremy Loehr 3, Dennis A. Romero6, Christophe Fremaux7, Philippe Horvath 7,
Yannick Doyon 3, Christian Cambillau 4,5 & Sylvain Moineau 1,8
CRISPR-Cas systems are bacterial anti-viral systems, and bacterial viruses (bacteriophages,
phages) can carry anti-CRISPR (Acr) proteins to evade that immunity. Acrs can also fine-tune
the activity of CRISPR-based genome-editing tools. While Acrs are prevalent in phages
capable of lying dormant in a CRISPR-carrying host, their orthologs have been observed only
infrequently in virulent phages. Here we identify AcrIIA6, an Acr encoded in 33% of virulent
Streptococcus thermophilus phage genomes. The X-ray structure of AcrIIA6 displays some
features unique to this Acr family. We compare the activity of AcrIIA6 to those of other Acrs,
including AcrIIA5 (also from S. thermophilus phages), and characterize their effectiveness
against a range of CRISPR-Cas systems. Finally, we demonstrate that both Acr families from
S. thermophilus phages inhibit Cas9-mediated genome editing of human cells.
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The rapid progression of CRISPR-Cas technology, from thediscovery of its DNA cutting-activity1 to its widespreadadoption as a genome-editing tool, has been astonishing.
Its native function as a bacterial anti-viral system was uncovered
in the dairy bacterium Streptococcus thermophilus a decade ago2.
Upon exposure to strictly lytic streptococcal viruses (bacter-
iophages or phages), only a few bacterial cells would survive
having incorporated a short 30 nucleotide (nt) sequence matching
phage genomic DNA into the “memory” of this adaptive immune
system: the CRISPR array2. This array is transcribed to form short
RNAs named crRNAs, which serve to lead the Cas9 nuclease to
its DNA cleavage target through RNA-DNA base-pairing, thereby
providing CRISPR immunity3. For genome-editing applications, a
synthetic version known as the single-guide RNA (sgRNA) can be
designed to direct Cas9 to its target4,5. Even in the initial dis-
covery of the anti-phage role of CRISPR-Cas systems in bacteria,
it was evident that phages had means of bypassing that immunity
—a phage with a single point mutation in the 30-nt sequence
targeted by the crRNA2, or in the flanking proto-spacer adjacent
motif (PAM)6 could freely infect the CRISPR-immunized bac-
terial host. This came as no surprise, as phages and bacteria are
locked in an arms race as old as they are. What was surprising,
given the ease with which phages bypass this immunity, was the
discovery of phage proteins specifically interfering with CRISPR-
Cas systems: anti-CRISPRs (Acrs)7.
The field of Acrs has rapidly garnered interest, largely due to
potential applications modulating the cleavage activity of various
Cas9 proteins. Tight control over Cas9 could prevent off-target
cleavage in genome-editing applications8, or lock Cas9 into useful
catalytically inactive states9. Bioinformatic methodologies have
uncovered a number of Acrs that interfere with different types of
CRISPR-Cas systems10–13 in a variety of manners9,13–20. To date,
the in-depth characterization of eight Acrs (four against type I,
four against type II CRISPR-Cas systems21,22) has revealed at
least six distinct mechanisms of action13,20,23. Initially these Acrs
were invariably found in temperate phages (phages that can enter
a latent “prophage” state in the bacterial genome), prophage
remnants, and horizontally acquired genomic islands23. In 2017,
Acrs were discovered in the genomes of virulent phages—phages
that cannot become prophages—infecting Listeria mono-
cytogenes24 and S. thermophilus25. Even for the two Acrs detected
in virulent phages (AcrIIA4 from L. monocytogenes and AcrIIA5
from S. thermophilus), the majority of their homologs were found
in temperate phages24,25. While this is likely a reflection of the
relative paucity of virulent phage sequences, it could also imply
that the short-lived association of a virulent phage with its host
would reduce the benefits of carrying an Acr. Virulent phages
might also simply have distinct Acrs, given the different evolu-
tionary pressures they face. Supporting this notion, the AcrIIA4
homologs in virulent Listeria phages share at most 41% ID with
the reference from a prophage. Interestingly, the Acrs with
orthologs in virulent phages are two (AcrIIA4 and AcrIIA5) of
the only three (alongside AcrIIA2) to block the activity of the
genome-editing tool SpCas94,26, derived from the type II-A
CRISPR-Cas system of Streptococcus pyogenes22. Of these three
proteins with demonstrated inhibition of SpCas9, only the
structure and mode of action of AcrIIA4 are known8,27,28.
AcrIIA4 competes with the dsDNA target of the SpCas9-sgRNA
complex through interaction with the PAM-binding domain27,28.
In this study, we take advantage of the CRISPR immunity in S.
thermophilus29 and a large collection of virulent phages as
hunting ground for new Acrs. We probe a dataset of 254 (largely
virulent) S. thermophilus phage genomes, including new public
genomic sequences30 as well as our set of phage genomes, to
search for Acrs. We capitalize on a methodology25 derived from
bacterial CRISPR-based immunization31,32, armed with the
knowledge that activity against one of the two distinct S. ther-
mophilus type II-A CRISPR-Cas systems (CR1/St1Cas9 and CR3/
St3Cas9) can yield Acrs with activity against SpCas925.
Results
Discovery of new Acrs. AcrIIA5 was previously discovered in the
virulent phage D4276, infecting S. thermophilus strain
DGCC7854, after the phage was found to bypass CRISPR
immunity against it25. We identified another virulent phage
infecting the same strain, phage D1811. When strain DGCC7854
was challenged with phage D1811, only a small proportion of the
surviving colonies had acquired a new spacer in their CRISPR
arrays, in contrast to what is typically observed during CRISPR-
based immunity (Fig. 1a). Genome analysis indicated that phage
D1811 did not contain acrIIA5 or a homolog thereof. Further-
more, when used to challenge a CR1-immunized strain targeting
a 30-nt conserved phage genomic region flanked by a suitable
PAM, phage D1811 was still able to form plaques and replicate
efficiently—even better than phage D4276, which harbors acrIIA5
(Fig. 1a). This led us to believe that the virulent S. thermophilus
phage D1811 possessed an unidentified Acr.
We compared the genome organization of the two phages and
observed that the acrIIA5 gene in the genome of phage D4276 is
located downstream of a conserved gene (Fig. 1b, pink), which is
also present in D1811. As gene neighborhood analysis has been
useful in other cases of Acr discovery12, we cloned the D1811
gene (D1811_026) located downstream of this conserved gene to
check for anti-CRISPR activity. Expression of the putative acr on
a plasmid in a CR1-immunized S. thermophilus strain completely
abolished immunity against the CRISPR-sensitive virulent phage
D5842 (Fig. 1c, green), and even eliminated the residual
resistance observed against phage D1811 (Fig. 1c, red). This
new Acr, which bears no similarity to any Acr characterized to
date, was named AcrIIA6.
AcrIIA6 proved difficult to characterize using standard
bioinformatics tools—neither it, nor the predicted proteins whose
genes are flanking acrIIA6 had any recognizable motif, e.g., helix-
turn-helix (HTH) or coil-coil motifs, previously associated with
other Acrs (Fig. 2a). A distinguishing feature of the protein was
its size. At 183 amino acid (aa) residues, it is the largest (+23%)
known type II-A Acr. Interestingly, the few orthologs of AcrIIA4
found in virulent phages were ~70% larger (148 aa) than their
counterparts in prophages, and were similarly not found adjacent
to proteins with HTH motifs present for their prophage
orthologs24. We used AcrIIA6 to probe S. thermophilus phage
sequences for homologs of the protein. Remarkably, 90 out of the
254 (35.4%) phage genomes contained an acrIIA6 ortholog
(criterion= 75% nucleotide identity (ID) over 75% of the gene
length). The same 90 sequences were returned using less stringent
criteria; 40% ID over 40% of the gene length. Of note, 81 of these
genes were found in the genome of 242 virulent S. thermophilus
phages (33.5% prevalence) (Fig. 2b), while nine of them were
found in 12 temperate phages (75% prevalence). By comparison,
only 14 (5.5%) out of the 254 genomes contained an acrIIA5
ortholog, and no phage genome contained both acrIIA5 and
acrIIA6 (Fig. 2b). The prevalence of AcrIIA6 in virulent phages is
lower than that of AcrIIA4 (16/23 public complete genomes). It
is noteworthy that all 12 known S. thermophilus temperate phages
contained either an acrIIA5 (25%) or acrIIA6 (75%). This may
suggest a greater need for genetic elements that associate long-
term with a bacterium to evolve solutions to CRISPR-Cas
immunity. Furthermore, these Acrs are very similar (minimum
76.5% amino acid ID across all of them) to their homologs in
virulent phages, in contrast to the Listeria AcrIIA4s (up to 41%
ID to a temperate phage Acr).
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There are currently four groups of genetically distinct S.
thermophilus phages30,33–35, but there was noclear association
between the presence or absence of a known Acr and a phage
group (Fig. 2b)., Nor could we correlate the presence of an AcrIIA
family in a phage to the CRISPR-Cas systems present in its hosts
(Fig. 2c). Across 90 phages carrying acrIIA6, 48 different protein
alleles were observed (Supplementary Fig. 1), while in 14 acrIIA5-
carrying phages, we identified 11 unique protein alleles
(Supplementary Fig. 2). No AcrIIA5 and AcrIIA6 shared any
similarity. This discovery of two distinct families of Acrs disabling
S. thermophilus CRISPR immunity is not unprecedented:
AcrIIA1-4 are all very different but impede the same L.
monocytogenes Cas924.
Structure of AcrIIA6. With bioinformatic predictions yielding
little information (Fig. 2a, c), we set about the biochemical
characterization of AcrIIA6. It crystallized readily and its struc-
ture was solved at 1.96 Å revealing a dimeric assembly (Fig. 3,
Supplementary Table 1). Gel filtration profiles also indicated that
AcrIIA6 is a dimer in solution (Supplementary Fig. 3). Each
monomer consists of eight α-helices and four β-strands forming a
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Fig. 1 Discovery of a new Acr. a Profiles of immunity generation (top, where n= the number of survivors screened) and ability to bypass immunity
(bottom) of CRISPR-sensitive (green), CRISPR-resistant (red), and CRISPR-intermediate (ochre) phages. Log reductions from three technical replicates.
b Representation of the genomic region in which acrIIA5 was found in D4276 for each phage in a. ORFs, represented by an arrow, are color-coded if their
product shares >50% aa identity with another elsewhere in any of the other phages, and white if it does not. Functions are annotated for the first instance
of any ortholog. “Acr?” was investigated for being downstream of a gene (pink) conserved in D4276. c Titres of a CRISPR-sensitive (green) or CRISPR-
resistant (red) phage on their host or a CR1-immunized version thereof, in the presence or absence of the putative Acr. The presence of the Acr restores
the titre of both phages to the levels observed in the absence of immunity. The titres are from three biological replicates, each of three technical replicates.
Error bars represent standard deviation, and a star (*) indicates a significant difference from each other column in the graph, as calculated by one-way
analysis of variance (ANOVA) and Tukey honest significant difference (HSD) test (p < 0.01)
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β-sheet, with the sequence topology α1α2α3α4α5α6α7β1β2β3β
4α8 (Fig. 3a, b). Two other Acrs have been reported to form
dimers19,20: AcrF3 interacts with the Cas3 subunit of type I-F
CRISPR-Cas systems, which is not present in type II-A systems,
while AcrIIA1 was found to co-purify with RNA, leading the
authors to suggest that it interacts with nucleotides directly.
When the AcrIIA6 structure was submitted to the DALI
server36, only low scores of structural similarity were returned.
The best score (Z= 4.1 and rmsd of 2.3 Å for 71 aligned residues)
was obtained with the HTH domain of an Escherichia coli
putative transcription factor (PDB 2ef8). Superimposition of
helices 1–5 from the AcrIIA6 monomer onto the 2ef8 monomer
confirms an HTH domain in the Acr (Fig. 3c). This feature was
not detectable by bioinformatic analyses of the protein sequence
(Fig. 2a). The AcrIIA6 HTH domain is part of the dimerization
interface, which is also similar to that of the bona fide HTH
domain present in an E. coli controller protein C.Esp1396I solved
in complex with dsDNA (PDB 3s8q)37. The superimposition of
the AcrIIA6 HTH dimer onto the C.Esp1396I-dsDNA complex
brings the AcrIIA6 helix 3 into contact with the two major
grooves of the dsDNA (Fig. 3d). Helix 3 exhibits strong
electropositivity, a feature observed in dsDNA binding helices,
including the one from C.Esp1396I. Bio-layer interferometry
(BLI) indicated binding to dsDNA, ssDNA, and a dsDNA-ssRNA
duplex (Supplementary Fig. 4), but we do not know at this time if
that affinity is altered by interaction with St1Cas9. A very recent
study of the dimerizing AcrIIA1 revealed that it also contains an
HTH domain20, and co-purifies with RNA when over-expressed
in E. coli. Aside from this similarity the two structures differ
considerably, as AcrIIA1 is formed exclusively of α-helices. We
could not dock the AcrIIA6 structure to that of St1Cas9, as the
latter is not available. We mapped the sequence conservation
among the 48 unique AcrIIA6 alleles to the structure obtained
(Supplementary Fig. 1). The dimerization interface is largely
conserved as are the DNA-interacting arms of the HTH motif.
Comparing AcrIIA activities. Since AcrIIA5 and now AcrIIA6
were discovered in phages infecting the S. thermophilus strain
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DGCC7854, a host containing only a single type II-A system
(CR1, associated with St1Cas9), we decided to investigate the
activities of Acrs orthologs from virulent phages infecting S.
thermophilus hosts with two distinct type II-A systems; CR1 and
CR3 (associated with St3Cas9). We reasoned these orthologs
might have broader specificity. For AcrIIA5, we chose an ortholog
present in phage D1126 (87% aa ID), whose host, DGCC7710, is a
model for CRISPR immunity and whose CR1 and CR3 systems
are well characterized, with the former being more active38. For
AcrIIA6, we chose an ortholog (92% ID) from the reference
phage DT139 whose host, SMQ-301, also contains both CR1 and
CR3 systems. We were also surprised to find an AcrIIA6 ortholog
(92% ID) in phage D1024, which had displayed limited Acr
activity in our earlier assays (Fig. 1a)—suggesting that the few
differences between these two Acrs might be mechanistically
relevant. The sequences of these 5 Acrs are compared in Sup-
plementary Fig. 5. Furthermore, we compared the activities of
these Acrs to those of the L. monocytogenes Acrs, AcrIIA2, and
AcrIIA4. We cloned each of them into a vector for expression in
two lactic acid bacteria. We then challenged S. thermophilus cells,
immunized through either CR1 (St1Cas9) or CR3 (St3Cas9)
system, or Lactococcus lactis cells immunized using an exogenous
plasmid-borne SpCas9, with their respective virulent phages 2972
(S. thermophilus) or p2 (L. lactis). Of note, SpCas9 (1368 aa) is
more similar to St3Cas9 (1409 aa, 57% ID) than to the shorter
St1Cas9 (1121 aa, 17% ID).
All AcrIIA6 and AcrIIA5 orthologs completely restored the
plaquing efficiency of phages targeted by the CR1 system of S.
thermophilus (Fig. 4), indicating they are blocking the activity of
St1Cas9. It is noteworthy that S. thermophilus phage D1024,
which is carrying a distinct allele (acrIIA6D1024) in its genome, is
only partially capable of bypassing CR1 immunity
natively (Fig. 1a)—the increased effectiveness observed with the
plasmid-borne acrIIA6D1024 version is likely reflective of a higher
copy gene number, and its expression prior to phage entry.
Similarly, the CRISPR-resistant phage D1811 (Fig. 1c) titres
increased when its Acr was expressed from a plasmid. Neither
Listeria AcrIIA2 nor AcrIIA4 displayed any effectiveness against
the streptococcal CR1 system.
CR3-immunity was unaffected by any AcrIIA6 ortholog
(Fig. 4), while both AcrIIA5s were effective against the
CR3 system (Fig. 4). Notably, AcrIIA5D4276 comes from a phage
infecting a S. thermophilus host which lacks the CR3 locus, and its
activity is limited to a 10-fold inhibition of CR3 activity25. In
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Fig. 3 Crystal structure of AcrIIA6. a Ribbon view of the AcrIIA6 dimer. The left monomer is rainbow-colored, the right monomer is colored in beige. The
secondary structures are identified α1–α8, β1–β4. b Surface representation with the same orientation and colors as in a. c Superimposition of AcrIIa6
monomer A (magenta) on a monomer of a putative transcription factor (PDB 2ef8, green). Helices α1–α5 are structurally aligned. d Superimposition of the
AcrIIa6 dimer (blue) on the controller protein C.Esp1396I operator (yellow) in complex with dsDNA (orange; PDB 3s8q37). Both helices α3 are inserted in
adjacent major grooves
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contrast, AcrIIA5D1126 (87% ID with AcrIIA5D4276), which
originates from a phage infecting a strain (DGCC7710) carrying
both CR1 and CR3 systems, can completely inhibit St3Cas9’s
activity—the first reported Acr to do so.
We also tested the seven AcrIIAs for their ability to impede an
exogenous plasmid-borne SpCas9 in the L. lactis model. AcrIIA6s
did not impede SpCas9, while AcrIIA2 and AcrIIA4 exhibited
only a partial inhibition. Both AcrIIA5s almost completely
abolished SpCas9 activity in this bacterial system (Fig. 4). We
had previously reported that this lactococcal phage assay is
leaky25, with plaque morphology also corresponding to the
effectiveness of the Acr. Plaque sizes corresponded with the
efficacy observed in Fig. 4 (Supplementary Fig. 6).
Genome-editing applications. The lactococcal SpCas9 assay,
though very useful for side-by-side comparisons of Acrs, has
shortcomings for evaluating genome-editing potential. In addi-
tion to the non-eukaryotic background, the assays are performed
at 33 °C, close to L. lactis’ optimal growth temperature (30 °C),
rather than at 37 °C. Therefore, we evaluated the effectiveness of
the seven AcrIIAs against the two more distant relatives, SpCas9
and St1Cas9, in human K562 cells. In addition to SpCas9,
St1Cas9 has been used previously in genome-editing applications,
due to its different PAM specificity40. Following transient over-
expression of the Cas9s and Acrs, we determined the frequency of
Cas9-induced indels in treated cells using the Surveyor
nuclease41.
In agreement with previous studies8, we observed near
complete inhibition of SpCas9 activity at three different targets
with AcrIIA4 (Fig. 5a). However, AcrIIA4 demonstrated no
activity against St1Cas9 (Fig. 5b). This inhibition profile is
consistent with its known mode of action: interacting with the
PAM-recognition domain of SpCas927,28. As SpCas9 and the
Cas9 from Listeria require the same (NGG) PAM, share the same
DRKRYT specificity motif, and are identical at 15 (similar at 17)
of the 19 residues identified as interacting with AcrIIA427,28,
AcrIIA4 robustly inhibits SpCas9 but has no effect on Cas9
proteins recognizing other PAMs.
None of the three AcrIIA6 orthologs had any detectable effect on
SpCas9 (Fig. 5a), confirming the results observed with the L. lactis
system, but all three were capable of inhibiting St1Cas9, with
residual nuclease activity observed at only one target for
AcrIIA6D1811. Further validating the L. lactis system, we observed
no detectable activity of AcrIIA2 against any Cas9 in this assay.
While AcrIIA2 and SpCas9 do interact in vitro27,30,42, our data
show that these interactions are not always indicative of utility in
the context of genome-editing applications. Some effectiveness of
AcrIIA2 on SpCas9 was previously demonstrated in
HEK293T cells24. It should be noted that the levels of inhibition
observed might not only reflect the potency of the Acrs, but also
their expression and functionality in these ectopic contexts. Notably,
the steady state levels of the AcrIIAs expressed from the AAVS1 safe
harbor locus in human cells varied (Supplementary Fig. 7).
Of all the Acrs tested in human cells and in the bacterial assays,
AcrIIA5 displayed the broadest range of activity (Figs. 4, 5). It
could completely inhibit SpCas9 at two targets, providing ~60%
inhibition at the other site, and also proved to be an equally
potent inhibitor of St1Cas9. The activities of all tested Acrs in our
assays are summarized in Table 1. A concurrent in vitro study
also observed a wide range of AcrIIA5 activities, stretching so far
as to inhibit the type II-C Cas9 proteins of Neisseria meningitidis
and Campylobacter jejuni42.
Conclusions
Delving into the phages of S. thermophilus has yielded a new Acr
family, AcrIIA6, and an associated structure. While 38% of the
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virulent S. thermophilus phages analyzed contain AcrIIA5 or
AcrIIA6, surprisingly all temperate S. thermophilus phages known
to date possess one of these two AcrIIAs. These findings confirm
that virulent phages can carry Acrs, and, in contrast with previous
findings, the Acrs are closely related between virulent and tem-
perate phages. This may be a result of stronger selection for Acr-
containing virulent phages from repeated use of CRISPR-
immunized strains in industrial settings. Acrs with orthologs in
virulent phages have also consistently proven effective in genome-
editing applications. AcrIIA5 displays the broadest type II-A Acr
activity to date, in bacteria, in human cells, and in vitro. Our
findings support the notion that the phage-host interactions in S.
thermophilus, and possibly other bacterial systems, are strongly
influenced by Acrs. For example, the CR3 system of S. thermo-
philus strain SMQ-301 was thought to be inherently more active
than the co-occurring CR1 system, but this is a result of the
AcrIIA6 carried by the phage used to challenge it, DT1. This
raises interesting questions: S. thermophilus strains typically
contain up to four CRISPR-Cas systems—two have been con-
sidered dormant because phage challenges have never revealed
acquisition of new spacers at these loci. It is tempting to speculate
that these loci appear silent because Acrs are far more widely
spread than initially suspected in S. thermophilus.
Methods
Bacterial cultures. Strains and plasmids used in this study are listed in Supple-
mentary Table 2. S. thermophilus cultures were grown in M17 medium (Oxoid)
with 0.5% w/v lactose (LM17). If the plasmid pNZ123 was present, 5 μg ml−1
chloramphenicol was added to the medium. Overnight S. thermophilus cultures
were grown at 37 °C without shaking, but same-day cultures were grown at 42 °C.
L. lactis cultures were grown in M17 medium with 0.5% w/v glucose (GM17). If the
plasmid pNZ123 or pL2Cas9 was present, 5 μg ml−1 chloramphenicol or ery-
thromycin was added, respectively. L. lactis cultures were grown at 30 °C without
shaking. If phages were to be added, the medium was further supplemented with
10 mM CaCl2. E. coli cultures were grown in LB medium at 37 °C with shaking. If
the pNZ123 plasmid was present in the E. coli strain, 20 μg ml−1 chloramphenicol
was added.
Phage amplification and titration. Scrapings of phage lysates preserved at −80 °C
with 15% glycerol were co-inoculated with their host strain until complete lysis
occurred. This lysate was then filtered through a 0.45 μm PES filter and 100 μl of
the filtrate was used to inoculate the host strain grown to an OD600 of 0.1. This
second amplification lysate was also filtered (0.45 μm PES filter) and stored at 4 °C.
Phage titres were obtained through serial dilutions of phage lysate in buffer (50 mM
Tris-HCl, pH 7.5, 100 mM NaCl, 8 mM MgSO4). One hundred microliters of
diluted phage lysate and 300 μl of an indicator strain grown to an OD600 of 0.6 were
co-inoculated into 3 ml of molten 0.75% agar medium at 55 °C. The molten mix
was then rapidly poured onto a plate of the same medium with 1% agar, and
allowed to set. The plates were incubated overnight, and plaques were counted on
those plates with dilutions resulting in between 30 and 300 plaques. For small
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lactococcal plaque counting as shown in Supplementary Fig. 6, 0.4% molten LE
agarose was used instead, and incubation was done at 33 °C to reach a temperature
closer to S. pyogenes optimal growth temperature (source of SpCas9).
Immunizing assays. Phages were diluted in phage buffer in order to obtain a final
multiplicity of infection of 0.1 plaque-forming unit per colony forming unit (pfu/
cfu). Phages were plated with S. thermophilus DGCC7854 as described above for
phage titres, but surviving colonies (rather than plaques) were counted. Surviving
colonies (bacteriophage insensitive mutants) were screened by PCR for acquisition
of new spacers at the CR1 locus (DGCC7854) using primers described in Suple-
mentary Table 2. An increase in the size of the PCR product relative to the wild
type was indicative of CRISPR immunization.
Phage genome sequencing and annotation. The DNA of phage D1811, D1024,
and D5842 was extracted using a PureLink Viral RNA/DNA kit (Invitrogen, MA,
USA), and sequenced on a MiSeq system using a MiSeq reagent kit v2 after
preparation using the Nextera XT DNA library preparation kit (Illumina, British
Columbia, Canada). The genome was assembled using Ray v. 2.2.043 and annotated
through GeneMark.hmm prokaryotic44 and ORF-FINDER45. These annotations
were manually curated based on comparisons to related phages. The annotated
genomes were deposited in GenBank (accession numbers listed in Supplementary
Table 2).
Phage gene cloning for each pNZAcr construct. Primers (listed in Supplemen-
tary Table 2) were designed to amplify the S. thermophilus phage acr genes of
interest and their ribosome binding site, as well as to add 30-nt extensions over-
lapping the pNZ123 multiple cloning site to facilitate Gibson assembly. In the case
of the AcrIIA2 and AcrIIA4 synthesized constructs, the upstream region was
replaced with that of AcrIIA5 to ensure a ribosome binding site known to be
functional in lactic acid bacteria, and a single nucleotide substitution (C-A) was
made to avoid the rare CGC arginine codon. The amplified gene was then cloned
by Gibson reaction into pNZ123 digested with XbaI. The resulting plasmid was
transformed into commercial NEB5a E. coli cells according to the manufacturer’s
recommendations (New England Biolabs, Ontario, Canada), then purified using a
Qiaprep Spin Miniprep kit. The purified plasmid was then transformed into the
relevant S. thermophilus and L. lactis strains through a glycine shock-based pro-
tocol followed by electroporation29,46. The sequence of the insert was confirmed by
sequencing using primers pNZins_F and pNZins_R.
AcrIIA5 and AcrIIA6 analyses. The protein sequences of AcrIIA5 and AcrIIA6
were subjected to analysis through BlastP47,48, HTH prediction49, pcoils50,
jPred451, and hhpred50. Their orthologs in phage genomes were identified using
BlastN48.
Protein expression and purification. AcrIIA6 was subcloned using the Gateway
cloning system into a bacterial expression vector pETG-20A (with an N-terminal
6His-TRX-tev tag). The protein was overexpressed in E. coli Rosetta pLyS cells
cultured in NZY auto-induction medium (NZYTech) at 25 °C for 24 h. Cells were
harvested by centrifugation (4000 × g for 10 min), and the pellet was homogenized
and frozen in lysis buffer (20 mM Hepes pH 7.5, 150 mM NaCl, 5 mM imidazole,
0.1 mg ml−1 lysozyme, 1 mM phenylmethylsulfonyl fluoride (PMSF)). After
thawing, DNAse I (20 μg ml−1) and MgSO4 (1 mM) were added and cells were
lysed by sonication. The pellet and soluble fractions were separated by cen-
trifugation (16,000 × g for 30 min). The soluble fraction from the lysate was pur-
ified by affinity chromatography using a 5 ml HisTrap FF crude (GE Healthcare)
Ni2+-chelating column equilibrated in buffer A (20 mM Tris pH 8.0, 150 mM
NaCl, 5 mM imidazole). The protein was eluted with buffer A supplemented with
250 mM imidazole and was further purified by a size exclusion chromatography
(HiLoad 16/600 Superdex 200 prep grade, GE) equilibrated in 20 mM Hepes pH
7.5, 150 mM NaCl. The 6His-TRX tag was removed by addition of 1:10 (mol:mol)
of TEV protease and incubation for 48 h at 20 °C. The cleaved AcrIIA6 protein was
eluted from HisTrap FF crude Ni2+-chelating column and was further separated by
size exclusion chromatography (Hiload 26/600 Superdex 75 prep grade, GE
Healthcare) with 20 mM Hepes pH 7.5, 150 mM NaCl. Purity of the protein was
monitored at all stages of the purification using SDS–PAGE, and visualized by
Coomassie blue staining.
Crystallization and structure determination. The purified AcrIIA6 was con-
centrated to 7 mg ml−1 using an Amicon concentrator (Millipore). Initial crys-
tallization trials of AcrIIA6 were performed by the sitting-drop vapor-diffusion
method at 293 K in 96-well Swissci plates using a Mosquito Crystal robot (TTP
Labtech) with the following screens: Stura Footprint Screens (Molecular
Dimensions), Pact1er (Molecular Dimensions), Wizard I and II (emerald), JCSG
+ Suite (Qiagen/Nextal), and amSO4 Suite (Qiagen/Nextal). Crystallization hit
occurred in condition No. B8 of the JCSG+ Suite [200 mM Magnesium chloride,
100 mM Tris pH 7, 10% (w/v) PEG 8000]. After optimization52, the final crys-
tallization conditions were 0.2 M magnesium chloride, 0.1 M Tris pH 6.5–7.5,
5–15% (w/v) PEG 8000. Crystals were briefly soaked in crystallization solution
supplemented with 20% (v/v) propylene glycol. Before flash cooling in liquid
nitrogen, a heavy atom derivative was produced by soaking crystals in a solution
of tantalum bromide cluster (Ta6Br12:Br2), leading to crystals becoming green in
few seconds. A fluorescence scan was performed to determine the peak wave-
length (0.9882 Å). Single-wavelength anomalous diffraction data were collected
to 2.9 Å resolution on Ta6Br12:Br2 soaked AcrIIA6 crystals at beamline Proxima-
1 at SOLEIL (Paris, France). Native AcrIIA6 diffraction data sets were collected
on beamline Proxima-1 at Soleil, Paris, France (Supplementary Table 1). The
data sets were integrated with XDS53 and were scaled with SCALA from the
CCP4 Suite54. Then, auto-tracing was performed with BUCCANEER55 and
several iterations of model improvement were conducted by cycling through
refinement with autoBUSTER56, phase improvement by density modification
Table 1 Summary of AcrIIA activities
Bacterial Assays Human Assays
S. thermophilus
DGCC7710
S. thermophilus
DGCC7710
Lactococcus lactis
MG1363
K562 cells K562 cells
St1Cas9
(1121 aa)
St3Cas9
(1409 aa)
SpCas9
(1368 aa)
SpCas9 (1368
aa)
St1Cas9 (1121
aa)
AcrIIA2
(123 aa)
L. monocytogenes
prophage
− − + − −
AcrIIA4
(87 aa)
L. monocytogenes
prophage
− − + +++ −
AcrIIA5
D1126
(140 aa)
S. thermophilus phage
D1126
+++ +++ +++ ++ +++
AcrIIA5
D4276
(140 aa)
S. thermophilus phage
D4276
+++ + +++ ++ ++
AcrIIA6
D1024
(183 aa)
S. thermophilus phage
D1024
+++ − − − +++
AcrIIA6
D1811
(183 aa)
S. thermophilus phage
D1811
+++ − − − ++
AcrIIA6 DT1
(183 aa)
S. thermophilus phage
DT1
+++ − − − +++
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with PARROT54, auto-tracing with BUCCANEER55 and manual pruning and
rebuilding using COOT57. The cubic and tetragonal structures have 98.1% and
97.2% aa in the preferred regions of the Ramachandran plot, and no residue in
the outliers regions. The refinement statistics are presented in Supplementary
Table 1. A stereo image of a portion of the electron density map is available in
Supplementary Figure 8.
Bio-layer interferometry (BLI). AcrIIA6 binding to dsDNA, DNA-RNA hetero-
duplex, and ssDNA was measured using BLI. A 20-mer biotinylated target ssDNA
and its DNA and RNA complements were purchased from Integrated DNA Tech-
nologies (IDT) (Bio-ssDNA: 5′-AATACTTTTATCAACGCAAG-3’; ssDNA: 5′-
CTTGCGTTGATAAAAGTATT-3′; ssRNA: 5′-CUUGCGUUGAUAAAAGUATT-
3′). Oligo strands were resuspended in duplex buffer (30mMHEPES pH 7.5, 100mM
potassium Acetate), mixed in equal molar amounts, heated to 94 °C for 2min, and
gradually cooled down to form double-stranded targets according to IDT protocol.
Streptavidin-coated biosensors were used to immobilize biotinylated ligands and
monitor association and dissociation of AcrIIA6. All experiments were performed
using an Octet® Red96 system at 27 °C, with an agitation speed of 1000 rpm in the
interaction buffer (50mM HEPES pH 7.5, 100mM KCl, 2mM MgCl2, 0.01% Tween
20, 0.01 mgm−1 BSA). The consecutive steps of the BLI measurements were as
follows: 60 s incubation in buffer, 180 s in 250 nM of duplexes (ligand loading to a
signal of 0.7 nm), 60 s incubation in biocytin (quenching of biosensors surface), 60 s
wash in buffer, 120 s baseline measurement, 340 s association in 6 μM AcrIIA6, and
300 s dissociation in buffer. Association and dissociation curves were double refer-
enced against the buffer reference signal (biosensors coated with ligands and incu-
bated in buffer only), and the reference sensors signal (biosensors without ligands
and incubated in AcrIIA6). Data were analysed using the Fortebio Data Analysis
software 8.2.
Cell culture and transfection. K562 cells were obtained from the ATCC and
maintained at 37 °C under 5% CO2 in RPMI medium supplemented with 10% FBS,
penicillin-streptomycin, and GlutaMAX. Cells (2E5 per transfection) were trans-
fected using the Amaxa 4D-Nucleofector (Lonza) per manufacturer’s recommen-
dations. Targeted integration to the AAVS1 locus was achieved by co-transfection
of ZFNs (500 ng) and donor plasmids (1 µg)58. Pools of cells were selected for
10 days with 0.5 µg ml−1 puromycin starting 3 days post-transfection.
Plasmids and oligonucleotides used for K562 cell work. SpCas9 and associated
sgRNAs were expressed from pX4585 (Addgene plasmid #48138, a gift from Feng
Zhang). Human expression vectors for S. thermophilus St1Cas9 and associated
sgRNA were a gift from Keith Joung (Addgene plasmids #65775 and #65778)59.
Spacer (guide) sequences for SpCas9 and St1Cas9 have been described pre-
viously59,60 and are provided in Supplementary Table 3. Untagged AcrIIA proteins
were expressed transiently from a modified pVAX1 vector (Thermo Fisher Sci-
entific) containing a beta-globin intron. The AcrIIA ORFs were codon-optimized
for expression in human cells and synthesized as gBlocks gene fragments (IDT)
(Supplementary Table 4). To establish cell lines stably expressing the various
AcrIIAs, gBlock gene fragments were cloned into AAVS1_Puro_PGK1_3x-
FLAG_Twin_Strep (Addgene plasmid #68375)58.
Surveyor nuclease assays. Genomic DNA was extracted from 2.5E5 cells with
250 µl of QuickExtract DNA extraction solution (Epicentre) per manufacturer’s
recommendations. The various loci were amplified by PCR using the primers
described in Supplementary Table 5. Assays were performed with the Surveyor
mutation detection kit (Transgenomics) as described41. Samples were separated on
10% PAGE gels in TBE buffer. Gels were imaged using a ChemiDoc MP (Bio-Rad)
system, and quantifications were performed using the Image lab software (Bio-
Rad).
Flow cytometry. The frequency of mScarlet-I expressing cells was assessed with a
BD LSR II flow cytometer.
Data availability. Coordinates and structure factors for AcrIIA6 in a cubic native
and tetragonal native form have been deposited in the RCSB Protein Data Bank
under accession codes 6EYY and 6EYX, respectively. Nucleotide sequences for
genomes of phages D5842, D1024, and D1811 have been deposited in GenBank
under accession codes MH000602, MH000603, and MH000604, respectively. Other
relevant data supporting the findings of the study are available in this article and its
Supplementary Information files, or from the corresponding author upon request.
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